Vertex Pharmaceuticals Incorporated $VRTX Shares Bought by Alliance Wealth Advisors LLC UT

Key Points

• Alliance Wealth Advisors LLC UT increased its holdings in Vertex Pharmaceuticals by 68.2%, owning 1,573 shares valued at $763,000 by the end of the 1st quarter.
• Vertex Pharmaceuticals reported an earnings per share (EPS) of $4.52, exceeding analysts' expectations of $4.24, and a quarterly revenue of $2.94 billion.
• As of now, Vertex has a consensus rating of "Moderate Buy" from analysts, with a price target averaging $497.10.

Alliance Wealth Advisors LLC UT raised its stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) by 68.2% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,573 shares of the pharmaceutical company's stock after buying an additional 638 shares during the period. Alliance Wealth Advisors LLC UT's holdings in Vertex Pharmaceuticals were worth $763,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors also recently added to or reduced their stakes in the company. Clal Insurance Enterprises Holdings Ltd lifted its position in shares of Vertex Pharmaceuticals by 450.0% in the 1st quarter. Clal Insurance Enterprises Holdings Ltd now owns 55 shares of the pharmaceutical company's stock worth $27,000 after purchasing an additional 45 shares during the period. Mascagni Wealth Management Inc. purchased a new stake in shares of Vertex Pharmaceuticals in the 4th quarter worth approximately $31,000. SJS Investment Consulting Inc. lifted its position in shares of Vertex Pharmaceuticals by 46.2% in the 1st quarter. SJS Investment Consulting Inc. now owns 95 shares of the pharmaceutical company's stock worth $46,000 after purchasing an additional 30 shares during the period. University of Texas Texas AM Investment Management Co. purchased a new stake in shares of Vertex Pharmaceuticals in the 1st quarter worth approximately $46,000. Finally, Stone House Investment Management LLC purchased a new stake in shares of Vertex Pharmaceuticals in the 1st quarter worth approximately $48,000. 90.96% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of research firms recently commented on VRTX. Cantor Fitzgerald decreased their target price on shares of Vertex Pharmaceuticals from $535.00 to $485.00 and set an "overweight" rating for the company in a research report on Tuesday, August 5th. Wells Fargo & Company raised shares of Vertex Pharmaceuticals from an "equal weight" rating to an "overweight" rating and set a $460.00 target price for the company in a research report on Wednesday, August 6th. Stifel Nicolaus decreased their target price on shares of Vertex Pharmaceuticals from $494.00 to $455.00 and set a "hold" rating for the company in a research report on Tuesday, August 5th. Wolfe Research lowered shares of Vertex Pharmaceuticals from an "outperform" rating to a "peer perform" rating in a research note on Wednesday, May 7th. Finally, Morgan Stanley set a $439.00 price target on shares of Vertex Pharmaceuticals and gave the company an "equal weight" rating in a research note on Tuesday, August 5th. One investment analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and thirteen have given a Hold rating to the company. According to MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $497.10.

Vertex Pharmaceuticals Trading Up 0.2%

VRTX traded up $0.88 during midday trading on Tuesday, hitting $390.76. 1,699,731 shares of the company traded hands, compared to its average volume of 2,414,711. The company has a market capitalization of $100.19 billion, a price-to-earnings ratio of 27.93 and a beta of 0.44. Vertex Pharmaceuticals Incorporated has a 52-week low of $362.50 and a 52-week high of $519.88. The business has a 50 day simple moving average of $443.83 and a two-hundred day simple moving average of $463.61.

Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last posted its quarterly earnings data on Monday, August 4th. The pharmaceutical company reported $4.52 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.24 by $0.28. The business had revenue of $2.94 billion for the quarter, compared to the consensus estimate of $2.90 billion. Vertex Pharmaceuticals had a net margin of 31.86% and a return on equity of 23.91%. The company's revenue was up 11.3% compared to the same quarter last year. During the same period last year, the firm posted ($12.83) earnings per share. Vertex Pharmaceuticals has set its FY 2025 guidance at EPS. Equities research analysts anticipate that Vertex Pharmaceuticals Incorporated will post 15.63 earnings per share for the current year.

Insider Buying and Selling

In other Vertex Pharmaceuticals news, Director Bruce I. Sachs acquired 5,000 shares of the business's stock in a transaction on Wednesday, August 6th. The stock was bought at an average price of $389.68 per share, for a total transaction of $1,948,400.00. Following the acquisition, the director owned 45,000 shares in the company, valued at approximately $17,535,600. The trade was a 12.50% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through the SEC website. Insiders own 0.20% of the company's stock.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.